HPMA copolymer-conjugated pirarubicin in multimodal treatment of a patient with stage IV prostate cancer and extensive lung and bone metastases
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389013%3A_____%2F16%3A00456866" target="_blank" >RIV/61389013:_____/16:00456866 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1007/s11523-015-0379-4" target="_blank" >http://dx.doi.org/10.1007/s11523-015-0379-4</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s11523-015-0379-4" target="_blank" >10.1007/s11523-015-0379-4</a>
Alternative languages
Result language
angličtina
Original language name
HPMA copolymer-conjugated pirarubicin in multimodal treatment of a patient with stage IV prostate cancer and extensive lung and bone metastases
Original language description
Nanomedicine allows achievement of tumor-selective drug delivery because of the enhanced permeability and retention (EPR) effect of solid tumors. We report here the first clinical application of a new agent?HPMA copolymer-conjugated pirarubicin (P-THP)?with a molecular size of about 8 nm, or 38.5 kDa. A patient had advanced prostate cancer with multiple metastases in the lung, pelvis, femur, and perhaps the sacrum. In April 2013, this 60-year-old patient started treatment with leuprorelin and estradiol,which continued until July 2014, but the patient became refractory to this treatment. So the patient underwent proton beam radiotherapy targeted to the primary prostate cancer, and P-THP was administered for numerous metastatic tumor nodules concomitantly with radiotherapy. This combination therapy had remarkable results, with complete remission of multiple metastases in the lung and bone. The prostate-specific antigen (PSA) value was decreased from about 1000 ng/mL on April 30, 2013, t
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
CD - Macromolecular chemistry
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Targeted Oncology
ISSN
1776-2596
e-ISSN
—
Volume of the periodical
11
Issue of the periodical within the volume
1
Country of publishing house
FR - FRANCE
Number of pages
6
Pages from-to
101-106
UT code for WoS article
000370799400010
EID of the result in the Scopus database
2-s2.0-84958753513